Latest SCLC Stories
Presentations at 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology Point to Potential Strategies for Treatment of Small Cell, Non-small Cell, and Neuroendocrine Lung Cancers
Completion of Enrollment Expected in 2015; Progression-Free Survival Data Expected in mid-2016 LOS ANGELES, Sept.
Report Stems From National Grassroots Advocacy To Require New Strategic Plans Of Action To Address Deadliest Cancers WASHINGTON, July 1, 2014 /PRNewswire-USNewswire/ -- Today the National Cancer
Two antidepressants that aren’t often prescribed to patients could soon be recommended to serve a completely different purpose; ward off small cell lung cancer (SCLC).
Although numerous randomized clinical trials have demonstrated a benefit of chemotherapy for patients with small-cell lung cancer (SCLC), these trials have predominantly compared different chemotherapy regimens rather than comparing chemotherapy to best supportive care.
NEW YORK and SAN DIEGO, Feb. 14, 2011 /PRNewswire/ -- Polaris Group (Polaris) and The Ludwig Institute for Cancer Research (LICR) today announced the enrollment of the first patient in a Phase 2 clinical trial evaluating ADI-PEG 20 in the treatment of small cell lung cancer (SCLC).
MicroRNA study provides biomarker for survival in small cell lung cancer.
SOUTH SAN FRANCISCO, June 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 24 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced a clinical and regulatory update on its lead product candidate, picoplatin.
Research published in February's edition of the Journal of Thoracic Oncology investigates the utilization of surgery and the subsequent need for radiotherapy (RT) when treating stage I small cell lung cancer (SCLC).
- A transitional zone between two communities containing the characteristic species of each.